About this item:

193 Views | 67 Downloads

Author Notes:

Kris Ann P. Schultz, Division of Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, 2530 Chicago Ave South, Minneapolis, MN 55404; Phone: 612-813-5940; Fax: 612-813-6325; krisann.schultz@childrensmn.org.

We thank Michelle Roesler, Cynthia Ford and Jan Sheaffer for their assistance in manuscript preparation.

We thank Children's Cancer Research Fund, Children's Oncology Group, and the National Cancer Institute, and the participating survivors and their families for their support of this research.

The authors declare no affiliations with any organization that has a direct interest in the subject matter contained herein.

They have no conflicting financial interests to declare.


Research Funding:

Children's Cancer Research Fund;Children's Oncology Group; National Cancer Institute. Grant Numbers: U24CA55727, 5U10 CA07306, 1R01CA78960


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Hematology
  • Pediatrics
  • acute myeloid leukemia
  • bone marrow transplantation
  • chronic health condition
  • late effects
  • pediatric
  • quality of life

Health Conditions and Quality of Life in Survivors of Childhood Acute Myeloid Leukemia Comparing Post Remission Chemotherapy to BMT: A Report from the Children's Oncology Group


Journal Title:

Pediatric Blood and Cancer


Volume 61, Number 4


, Pages 729-736

Type of Work:

Article | Post-print: After Peer Review


Background: Therapy for childhood acute myeloid leukemia (AML) has historically included chemotherapy with or without autologous bone marrow transplant (autoBMT) or allogeneic hematopoietic stem cell transplantation (alloBMT). We sought to compare health-related quality-of-life (HRQOL) outcomes between these treatment groups. Procedure: Five-year survivors of AML diagnosed before age 21 and enrolled and treated from 1979 to 1995 on one of 4 national protocols were interviewed. These survivors or proxy caregivers completed a health questionnaire and an HRQOL measure. Results: Of 180 survivors, 100 were treated with chemotherapy only, 26 with chemotherapy followed by autoBMT, and 54 with chemotherapy followed by alloBMT. Median age at interview was 20 years (range 8-39). Twenty-one percent reported a severe or life-threatening chronic health condition (chemotherapy-only 16% vs. autoBMT 21% vs. alloBMT 33%; P=0.02 for chemotherapy-only vs. alloBMT). Nearly all (95%) reported excellent, very good or good health. Reports of cancer-related pain and anxiety did not vary between groups. HRQOL scores among 136 participants ≥14 years of age were similar among groups and to the normative population, though alloBMT survivors had a lower physical mean summary score (49.1 alloBMT vs. 52.2 chemotherapy-only; P=0.03). Multivariate analyses showed the presence of severe chronic health conditions to be a strong predictor of physical but not mental mean summary scores. Conclusions: Overall HRQOL scores were similar among treatment groups, although survivors reporting more health conditions or cancer-related pain had diminished HRQOL. Attention to chronic health conditions and management of cancer-related pain may improve QOL.

Copyright information:

© 2013 Wiley Periodicals, Inc.

Export to EndNote